MetaCap

Centene (CNC) vs Quest Diagnostics (DGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Centene (CNC) has outperformed Quest Diagnostics (DGX) over the past year, gaining 74.7% versus a gain of 35.0%. Over five years, DGX leads with a +66.7% price change compared with -13.7% for CNC. Centene is the larger company by market cap ($31.58 billion vs $28.42 billion), about 1.1 times the size.

On valuation, Centene trades at a lower forward P/E (11.4x vs 21.6x for Quest Diagnostics). Quest Diagnostics pays a dividend yielding 1.31%, while Centene does not currently pay one. Quest Diagnostics converts more of its revenue into profit, with a net margin of 9.0% versus -3.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNC+74.74%DGX+35.05%
+114%+48%-19%
Nov 21, 20251 yearNov 20, 2026
CNC-12.64%DGX+74.00%
+82%+5%-72%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNC versus DGX key metrics
MetricCNCDGX
Share price$63.78$258.28
Market cap$31.58B$28.42B
1-day change-2.74%-0.31%
YTD return+54.99%+48.84%
1-year return+74.74%+35.05%
5-year return-13.69%+66.69%
P/E ratio (TTM)21.9225.73
Forward P/E11.4521.55
EPS (TTM)$2.91$10.04
Dividend yield0.00%1.31%
Annual dividend$0.00$3.38
Revenue (latest FY)$194.78B$11.04B
Revenue growth (YoY)+19.44%+11.78%
Net income (latest FY)$-6.67B$992.00M
Gross margin7.30%33.21%
Operating margin-3.91%14.10%
Net margin-3.43%8.99%
52-week high$78.08$263.19
52-week low$31.63$171.18
Distance from 52-week high-18.31%-1.87%
Analyst consensusbuybuy
Avg. price target upside+19.33%-0.39%
Average volume5.09M1.03M
Shares outstanding495.07M110.02M
Employees61,10060,000
SectorHealth CareHealth Care
IndustryMedical SpecialitiesMedical Specialities

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CNC has outperformed DGX by 39.7 percentage points over the past year.
  • Quest Diagnostics offers a meaningfully higher dividend yield (1.31% vs 0.00%).
  • Quest Diagnostics is more profitable, keeping 9.0 cents of every revenue dollar as net income versus -3.4 cents for Centene.
  • Centene grew revenue faster in its latest fiscal year (+19.44% vs +11.78%).

About Centene

CNC stock →

Centene Corporation operates as a managed care company that provides programs and services to under-insured families, and commercial organizations in the United States. It operates through four segments: Medicaid, Medicare, Commercial, and Other.

Health Care · Medical Specialities · 61,100 employees

About Quest Diagnostics

DGX stock →

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Health Care · Medical Specialities · 60,000 employees

CNC vs DGX FAQ

Which is bigger, Centene or Quest Diagnostics?

Centene (CNC) is larger, with a market capitalization of $31.58B compared with $28.42B for Quest Diagnostics (DGX).

Which stock has performed better over the past year, CNC or DGX?

CNC returned +74.74% over the past 12 months, compared with +35.05% for DGX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, CNC or DGX?

CNC has the lower trailing P/E at 21.9, versus 25.7 for DGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Centene or Quest Diagnostics?

Quest Diagnostics pays a dividend yielding 1.31%, while Centene does not currently pay a regular dividend.

Are Centene and Quest Diagnostics in the same industry?

Yes. Both are classified in the Medical Specialities industry within the Health Care sector.

More comparisons